Ifeanyichukwu Ifechidere: Direct Oral Anticoagulants Broke Traditional Coag Testing
Ifeanyichukwu Ifechidere, Specialist Biomedical Scientist at Sheffield Teaching Hospitals NHS Foundation Trust, shared a post on LinkedIn:
”DOACs and the Lab Dilemma: When Anticoagulation Outpaced Our Tests
‘Direct oral anticoagulants broke traditional coag testing.’
That may sound dramatic—but in many ways, it’s true.
For decades, laboratories and clinicians relied on PT and APTT as the backbone of coagulation assessment. They were predictable, interpretable, and clinically actionable. Then came DOACs… and the rules changed.
The Problem: Familiar Tests, Unfamiliar Behavior
Direct oral anticoagulants (DOACs)—including factor Xa inhibitors and direct thrombin inhibitors—interact with coagulation assays in ways that are:
- Variable (reagent-dependent)
- Drug-specific
- Often misleading
PT and APTT are no longer reliable indicators of anticoagulant effect
- A normal PT/APTT does NOT exclude clinically relevant DOAC levels
- A prolonged result does NOT quantify anticoagulation
In short: we’re using tools built for a different era.
The Shift: From Global Tests to Targeted Assays
To truly understand DOAC activity, we need drug-specific testing strategies:
- Anti-Xa assays (calibrated for specific DOACs) are used for rivaroxaban, apixaban, edoxaban
- Dilute thrombin time (dTT) or ecarin-based assays are used for dabigatran
These assays provide:
- Quantitative insight
- Drug-level estimation
- Clinical relevance in bleeding, thrombosis, or urgent procedures
But access remains inconsistent—and interpretation isn’t always straightforward.
The Real Dilemma Isn’t the Lab… It’s the Gap
We’re facing a critical disconnect:
- Clinicians may request PT/APTT expecting clarity
- Labs know these tests may mislead in DOAC-treated patients
- Results are reported… but not always understood
‘Are clinicians clear on DOAC lab interpretation?’
In many cases—not fully. And that’s not a criticism—it’s a system challenge.
Where Do We Go From Here?
- Stronger lab–clinician communication
- Clear interpretative comments on reports
- Wider access to DOAC-calibrated assays
- Ongoing education across disciplines
Because the question is no longer ‘What’s the PT?’
It’s ‘What does this result actually mean for this patient on a DOAC?’
Bottom Line
DOACs didn’t just change anticoagulation therapy—they exposed the limitations of our legacy testing systems.
As laboratory professionals, we’re not just reporting numbers anymore.
We’re guiding interpretation in a new and evolving landscape.”

More posts featuring Ifeanyichukwu Ifechidere on Hemostasis Today.
-
Nov 19, 2026, 16:27263 PolyU Students and Staff Unite to Donate Blood – Hong Kong Red Cross Blood Transfusion Service
-
Nov 19, 2026, 16:16Billy Otieno: The Future of Blood Donation Lies Beyond Collection
-
Nov 19, 2026, 15:58Hema Goyal: Hematocon 2026 Bringing Together Knowledge, Innovation and Excellence in Hematology
-
Nov 19, 2026, 15:44Chukwuemeka Amarachi: Understanding Complex Blood Grouping Beyond Routine ABO And RhD Typing
-
Nov 19, 2026, 14:19Long-Read Sequencing Is Closing Diagnostic Gaps in Inherited Bleeding Disorders
-
Nov 19, 2026, 13:36Raja Prince: Protein S Silencing and the Future of Hemostatic Therapy
-
Nov 19, 2026, 13:26M. Sekip Altunkan: The Thrombotic Risk of Andexanet Alfa
-
Nov 19, 2026, 13:18Felice Gragnano: Personalizing Antiplatelet Therapy After PCI
-
Nov 19, 2026, 13:11When Postpartum Warning Signs Are Ignored – National Blood Clot Alliance